The activation of JNK, either by EGFR or chemotherapy agent, stabilizes BMI1 and MCL1 protein expressions through suppressing HUWE1 expression, which then promote tumour initiation and chemo‐resistance. The gene discussed is MCL1; the disease is neoplasm.